Abstract:<p>The discovery of the rapid-acting antidepressant effects of ketamine have (<a class="workspace-trigger" href="#bib1">1</a>) led to a paradigm shift in our perception of what is possible in treating severe depression, (<a class="workspace-trigger" href="#bib2">2</a>) spurred a wave of basic, translation, and clinical research, and (<a class="workspace-trigger" href="#bib3">3</a>) provided an unprecedented investigational tool to conduct longitudinal mechanistic studies that may capture behavioral changes as complex as clinical remission and relapse within hours and days of treatment. Unfortunately, these advances did not yet translate into clinical biomarkers or novel treatments, beyond ketamine. In contrast to slow-acting antidepressants where targeting the monoaminergic receptors identified several efficacious drugs with comparable mechanisms, the focus on the receptor targets of ketamine has failed in several clinical trials over the past decade. Thus, it is becoming increasingly crucial that we concentrate our effort on the downstream molecular mechanisms of ketamine and their effects on the brain circuitry and networks. In the current special issue, honoring the legacy of our mentor, friend and colleague Ron Duman, we provide a historical note on the discovery of ketamine and its putative mechanisms. We then detail the molecular and circuits effect of ketamine based on preclinical findings, followed by a summary of the impact of this work on our understanding of chronic stress pathology across psychiatric disorders, with particular emphasis on the role of synaptic connectivity and its brain network effects in the pathology and treatment of clinical depression.</p>

Neurobiology of the Rapid-Acting Antidepressant Effects of Ketamine: Impact and Opportunities